tiprankstipranks
Blurbs

Robert W. Baird Reaffirms Their Hold Rating on Biogen (BIIB)

Robert W. Baird analyst Brian Skorney maintained a Hold rating on Biogen (BIIBResearch Report) on July 26 and set a price target of $224.00. The company’s shares closed last Thursday at $214.20, close to its 52-week low of $187.16.

According to TipRanks.com, Skorney has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.1% and a 42.6% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $236.83, representing an 11.5% upside. In a report issued on July 20, Piper Sandler also maintained a Hold rating on the stock with a $200.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Biogen’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.59 billion and net profit of $1.06 billion. In comparison, last year the company earned revenue of $2.78 billion and had a net profit of $449 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.

Read More on BIIB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More